CRDF - Cardiff Oncology, Inc.
IEX Last Trade
3.92
1.470 37.500%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:18:51 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$2.45
1.47
60.00%
Fundamental analysis
22%
Profitability
25%
Dept financing
8%
Liquidity
50%
Performance
15%
Performance
5 Days
-7.98%
1 Month
60.00%
3 Months
46.27%
6 Months
73.45%
1 Year
166.67%
2 Year
208.66%
Key data
Stock price
$3.92
DAY RANGE
$2.45 - $4.04
52 WEEK RANGE
$1.51 - $6.42
52 WEEK CHANGE
$157.89
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Mark Erlander
Region: US
Website: cardiffoncology.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cardiffoncology.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Cardiff Oncology, Inc. develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer.
Recent news